Nab-rapamyci

Clinical Trials Overview

1 trials found
About Nab-rapamyci

Nab-rapamycin (also known as ABI-009) is an investigational drug currently being studied in clinical trials for various advanced cancers, including certain types of colorectal cancer. It is being tested in combination with another investigational drug called nivolumab. In the context of colorectal cancer, nab-rapamycin is being studied specifically in patients whose tumors are MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficient). These are specific characteristics of some colorectal cancers. The goal of the trials is to determine the right dose of nab-rapamycin and to see how effective the combination of nab-rapamycin and nivolumab is in treating these cancers. It is important to note that nab-rapamycin is not yet approved for use in colorectal cancer or any other cancer.

Category Investigational
Brand Name ** Currently investigational - no approved brand names available. The compound is also known as ABI-009. **
Mechanism Nab-rapamycin is classified as an mTOR inhibitor. mTOR (mammalian target of rapamycin) is a protein that plays a key role in cell growth, division, and survival. By inhibiting mTOR, nab-rapamycin aims to block signals that promote cancer cell growth and proliferation. The specific way nab-rapamycin interacts with mTOR and its precise effects on cancer cells are being further investigated in clinical trials.
1
Total Trials
0
Recruiting
0
Active
1
Completed
34
Total Enrollment
1
Countries
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
NCT03190174 Phase 1 Completed 34 patients
Start: Aug 2017
End: Dec 2021
INTERVENTIONAL
Medications: Nab-rapamycin Nivolumab
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in advanced Ewing's sarcoma, pe...
United States
View Details ClinicalTrials.gov Am I eligible?
Back to Drug Glossary View All Trials